A vaccine It slows the progression of one of the deadliest cancer Can be manufactured In bulk, researchers say.
The test has hoped patients after a test Increased existence of participants with Pancreas,
Researchers described the findings as “remarkable” and already started testing the efficiency of JAB between a large group. Pancreatic and intestinal cancer patients,
JAB uses a new type of immunotherapy, designed to improve vaccine delivery in lymph nodes, which helps the body to fight infection and disease.
Pancreatic and bowel cancer often make a mutation in a gene called KRAS, which plays an important role in the development of tumors, and scientists developed jab to recognize and attack this gene.
Study published in journal Nature therapyJab tested JAB on 20 patients with pancreatic cancer and five patients with bowel cancer.
When participants were followed after 20 months, 68 percent developed specific immune reactions to mutant cross tumor proteins.
Participants who had the strongest immune response remained cancer-free for longer than people with weak reactions.
Some patients survived about two years and five months after receiving the vaccine.
In comparison, three out of three of the 10 people suffering from pancreatic cancer survive for a year.
The poorest survival rate is due to late detection in pancreatic cancer. This usually does not cause symptoms in the early stages, and as it increases, it can cause abdominal pain, yellow, unexplained weight loss of the skin, and changes in stools.
Many patients see their cancer returning even after treatment such as radiotherapy and chemotherapy.
But the test showed that JAB can help prevent cancer from returning to more than 15 months.
Unlike other cancer Jabs, who are individual to individual patients, it is a single version of the vaccine, ELI-002 2p, which can be given to all patients which means that it can be manufactured in bulk and can be given more rapidly.
Dr. Dani Edmonds, Research Information Manager Cancer Research UKSaid: “It is promising to see that vaccines can help people with pancreatic and bowel cancer to free cancer for a long time.”
He said, “More research needs to understand why some people benefit from vaccines while others do not, so that we can ensure that we are beating cancer for all,” he said.
Professor Richard Sulivan, director of the Center for Conflict and Health Research at King’s College London, suggested that more research is required.
“There is some interesting science in this study, but it is a long way to prove any type of clinical utility,” he said.